Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Octenisept + Serasept is a combination of two topical antiseptic products used for wound disinfection and mucous membrane antisepsis. Octenisept contains octenidine dihydrochloride (0.1%) and 2-phenoxyethanol (2%), providing broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses. Its mechanism involves binding to negatively charged bacterial membranes, destabilizing them, and causing cell rupture. Octenisept is widely used for the antiseptic treatment of acute, chronic, surgical, traumatic wounds as well as mucous membrane disinfection prior to diagnostic or surgical procedures[1][6][8]. Serasept's composition is not clearly defined in the available sources; however, it is typically marketed as an antiseptic solution for wound care in some regions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on octenisept + serasept.